Evaluation of bile salt hydrolase inhibitor efficacy for modulating host bile profile and physiology using a chicken model system by Geng, Wenjing et al.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title Evaluation of bile salt hydrolase inhibitor efficacy for modulating host
bile profile and physiology using a chicken model system
Author(s) Geng, Wenjing; Long, Sarah L.; Chang, Yun-Juan; Saxton, Arnold M.;
Joyce, Susan A.; Lin, Jun
Publication date 2020-03-18
Original citation Geng W., Long S. L., Chang Y. J., Saxton A. M., Joyce S. A. and Lin, J.
(2020) 'Evaluation of bile salt hydrolase inhibitor efficacy for
modulating host bile profile and physiology using a chicken model
system', Scientific Reports, 10, 4941, (20 pp).  doi: 10.1038/s41598-020-
61723-7
Type of publication Article (peer-reviewed)
Link to publisher's
version
http://dx.doi.org/10.1038/s41598-020-61723-7
Access to the full text of the published version may require a
subscription.
Rights © The Author(s) 2020. Open Access This article is licensed under a
Creative Commons Attribution 4.0 International License, which
permits use, sharing, adaptation, distribution and reproduction in
any medium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or
other third party material in this article are included in the article’s
Creative Commons license, unless indicated otherwise in a credit
line to the material. If material is not included in the article’s
Creative Commons license and your intended use is not permitted
by statutory regulation or exceeds the permitted use, you will need
to obtain permission directly from the copyright holder. To view a
copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
http://creativecommons.org/licenses/by/4.0/.
Item downloaded
from
http://hdl.handle.net/10468/9818
Downloaded on 2020-04-12T06:20:10Z

1Scientific RepoRtS |         (2020) 10:4941  | https://doi.org/10.1038/s41598-020-61723-7
www.nature.com/scientificreports
evaluation of bile salt hydrolase 
inhibitor efficacy for modulating 
host bile profile and physiology 
using a chicken model system
Wenjing Geng1,5, Sarah L. Long2,3,5, Yun-Juan chang4, Arnold M. Saxton1, Susan A. Joyce2,3* & 
Jun Lin1*
Gut microbial enzymes, bile salt hydrolases (BSHs) are the gateway enzymes for bile acid (BA) 
modification in the gut. This activity is a promising target for developing innovative non-antibiotic 
growth promoters to enhance animal production and health. Compelling evidence has shown that 
inhibition of BSH activity should enhance weight gain by altering the BA pool, host signalling and lipid 
metabolism. We recently identified a panel of promising BSH inhibitors. Here, we address the potential 
of them as alternative, effective, non-antibiotic feed additives, for commercial application, to promote 
animal growth using a chicken model. In this study, the in vivo efficacy of three BSH inhibitors (caffeic 
acid phenethylester, riboflavin, carnosic acid) were evaluated. 7-day old chicks (10 birds/group) were 
either untreated or they received one of the specific BSH inhibitors (25 mg/kg body weight) via oral 
gavage for 17 days. The chicks in treatment groups consistently displayed higher body weight gain 
than the untreated chicks. Metabolomic analysis demonstrated that BSH inhibitor treatment led to 
significant changes in both circulating and intestinal BA signatures in support of blunted intestinal BSH 
activity. Consistent with this finding, liver and intestinal tissue RNA-Seq analysis showed that carnosic 
acid treatment significantly altered expression of genes involved in lipid and bile acid metabolism. 
Taken together, this study validates microbial BSH activity inhibition as an alternative target and 
strategy to antibiotic treatment for animal growth promotion.
Antibiotic growth promoters (AGPs), a panel of different classes of antibiotics delivered in feed at sub-therapeutic 
doses to target the gut microbiota, have been applied to induce consistent and reproducible weight gain in live-
stock since the 1940’s1. However, evidence of a link between AGP usage and the emergence of antibiotic-resistant 
microbes, including human pathogens of animal origin, has led to a European ban on AGPs since 2006 so that 
currently, there is a worldwide trend to limit their applications2,3. Thus, developing innovative non-antibiotic 
technology to replace AGPs is urgently required in order to maintain levels of animal production for food, with-
out impacting public health.
Characterization of the gut microbial community (microbiome) in response to AGP treatment is critical 
to improve our understanding of the modes of action of AGPs, and for developing non-antibiotic alternatives 
to AGPs2,4,5. One functional aspect that shows enormous potential is bile acid metabolism. Consistently, the 
growth-promoting effects of AGP has been highly correlated with decreased microbial bile salt hydrolase activity 
(BSH), a function that can negatively impact host fat digestion and lipid metabolism4,6. BSHs catalyze decon-
jugation of liver released amino conjugated bile acids (BAs) in the intestine and they serve as a class of gateway 
microbial enzymes controlling downstream microbial and host BA metabolism in the intestine6,7. Furthermore, 
extensive gut microbiome studies have demonstrated that AGP usage significantly reduces microbial popula-
tions of powerful BSH-producers in the intestine, including Lactobacillus species4. Indeed, more recently, in vivo 
evidence demonstrates that manipulation of BSH activity alone could significantly influence lipid metabolism, 
signaling functions, and weight gain in a murine host8.
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In light of these findings, we hypothesized that dietary supplementation with BSH inhibitors could alter 
host lipid metabolism and energy harvest and consequently enhance feed efficiency and body weight gain in 
animals raised for food supply. We have identified and characterized a unique Lactobacillus salivarius BSH 
enzyme with a broad conjugated BA substrate specificity of chicken gut origin9. This BSH was applied for effec-
tive high-throughput screening to identify a group of promising BSH inhibitors that could act as an alternative 
approach to AGPs10. Understanding the in vivo behavior of these BSH inhibitors is important in order to deter-
mine whether their oral administration can facilitate effective transit to the complex gastrointestinal tract and 
exert inhibitory effects on intestinal BSHs as well as to examine their impact. Examining BA signature changes 
and their effects on host gene expression in a consumer relevant model, the chicken, will inform the development 
of BSH inhibitors as effective non-antibiotic feed additives for non-antibiotic growth promotion.
In this proof-of-concept study, the in vivo efficacy of three promising BSH inhibitors, riboflavin, caffeic acid 
phenethylester (CAPE), and carnosic acid10, were evaluated using the chicken model system. We performed a 
cage trial with limited chicken number of 10 birds per group, as opposed to industry-oriented pen trial for com-
prehensive nutritional measurement, usually >120 birds per treatment group11. This study aimed to determine 
whether feed delivered BSH inhibitors could effectively induce BA changes and alter chicken body weight gain 
and feed efficiency. It further aimed to determine the influence of one BSH inhibitor, carnosic acid, on local 
(intestine) and systemic (liver) transcriptome responses in validating inhibitor action.
Results
Oral BSH inhibitor delivery revealed responder (RS) and non-responder (NRS) growth promo-
tion when compared to untreated animals. Seven day old chicks were randomly allocated into four 
groups (n = 10/group). Each group received none (50% propylene glycol control solution) or one of the BSH 
inhibitors via oral gavage (once a day) for 21 consecutive days. All of the chickens exhibited normal growth 
behavior and no mortality occurred during the 28 days of the experimental period. No weight loss was evident 
for any treatment administered relative to control animals (Table 1). In general, oral administration of each BSH 
inhibitor consistently enhanced overall body weight (BW) and actual BW gain at the different time-points and by 
24 days of age (Table 1). However, despite these trends the differences in BW and BW gain were not statistically 
significant (P > 0.05).
Food intake was determined for each group throughout the duration of this study and the feed conversion 
ratio (FCR), an indicator for feeding efficiency, was recorded (Table 1). Oral administration of each BSH inhibitor 
consistently led to lower FCR than that in the control group during feeding periods examined: day 14–17, day 
17–21, and day 21–24 despite a lack of significant difference (P > 0.05) (Table 1). However, FCR was significantly 
different during the initial period, for BSH inhibitor-treated groups (1.82, 1.85, and 1.75 for riboflavin, CAPE, and 
carnosic acid, respectively) than that of the control group (2.11).
Chicken 
Age Control CAPE Riboflavin Carnosic Acid P value
Chicken Body Weight (g/bird)
Day 7 163.56 ± 3.41 162.57 ± 4.92 164.19 ± 3.27 162.76 ± 3.32 0.99
Day 10 249.42 ± 5.83 244.91 ± 5.12 258.46 ± 4.96 251.58 ± 6.20 0.43
Day 14 421.16 ± 8.33 421.37 ± 9.88 431.98 ± 7.69 436.48 ± 8.87 0.54
Day 17 580.32 ± 10.68 585.68 ± 15.35 611.68 ± 13.50 601.10 ± 14.47 0.40
Day 21 813.11 ± 12.64 829.46 ± 22.95 869.59 ± 22.12 859.72 ± 22.03 0.25
Day 24 967.95 ± 20.89 1022.36 ± 29.85 1053.10 ± 33.74 1053.98 ± 26.77 0.19
Day 28 1234.26 ± 33.55 1294.11 ± 40.51 1304.03 ± 44.99 1293.40 ± 25.76 0.56
Chicken Body Weight Gain (g/bird/day)
Day 7–10 28.62 ± 0.95 27.45 ± 0.49 31.48 ± 0.98 29.58 ± 1.03 0.11
Day 10–14 42.99 ± 0.90 44.15 ± 1.27 43.33 ± 1.59 46.11 ± 1.35 0.48
Day 14–17 53.05 ± 1.97 54.77 ± 2.09 59.90 ± 3.56 54.87 ± 2.74 0.36
Day 17–21 58.20 ± 1.65 60.95 ± 2.55 64.48 ± 2.61 64.66 ± 2.37 0.23
Day 21–24 51.61 ± 3.96 64.30 ± 3.94 61.17 ± 5.43 64.75 ± 3.33 0.18
Day 24–28 66.67 ± 4.25 68.06 ± 4.53 62.78 ± 3.55 59.90 ± 3.28 0.52
Feed Conversion Ratio (g of feed/ g of weight gain)
Day 10–14 1.64 ± 0.03ab 1.56 ± 0.04b 1.81 ± 0.08 a 1.53 ± 0.05b 0.03
Day 14–17 2.03 ± 0.08 1.94 ± 0.09 1.92 ± 0.09 1.91 ± 0.13 0.84
Day 17–21 1.93 ± 0.05 1.82 ± 0.09 1.83 ± 0.08 1.66 ± 0.06 0.21
Day 21–24 2.49 ± 0.24 1.98 ± 0.15 2.15 ± 0.22 1.93 ± 0.11 0.22
Day 24–28 2.21 ± 0.14 2.15 ± 0.21 2.36 ± 0.16 2.31 ± 0.19 0.84
Table 1. Body weight, feed conversion ratio and body weight gain monitored over time in chickens treated 
or not with different BSH inhibitors over 21 days. Growth performance data (body weight, body weight gain, 
and feed conversion ratio) is represented as mean ± standard error. Different letters in the same row represent 
significant difference between treatments (Tukey, P < 0.05).
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When individual body weight and weight gain were examined over time following the different treatments, 
the animals could be stratified into two cohorts relative to the untreated group by principal component analysis 
(PCA analysis as shown in Fig. 1S). For each treatment non-responders (NRS) clustered with control, untreated 
animals while responders (RS) diverged and clustered together. On this basis, a threshold value of 1160 g/bird for 
NRS was calculated and any animal with a final weight above this value were classed as treatment RS. The actual 
division of animals on this basis for the different treatments are as follow: CAPE: RS n = 5, NRS n = 5; Riboflavin: 
RS n = 4, NRS n = 6; Carnosic acid: RS n = 4, NRS n = 6. Significant increases in body weight among RS was evi-
dent at 14 days for carnosic acid (P > 0.05) and at 17 days for both riboflavin and CAPE (P > 0.05) Fig. 1a–c. The 
RS body weight continued to increase significantly for the duration of the trial. The inhibitor potency to improve 
body mass among RS is as follows: riboflavin > CAPE > carnosic acid. When actual weight gain is measured 
(Fig. 1d–f), the potency varied in the order of riboflavin > carnosic acid > CAPE among RS. Accurate assessment 
of feed efficiency by RS and NS could not be performed since food intake was assessed collectively or per cage.
BSH inhibitor treatment alters BA profiles in the ileum. The collective effect of BSH (and its inhibi-
tors) on bile acid signatures can feedback to alter BA synthesis, BA ileal uptake, host signaling locally and system-
ically, as well as microbial populations. In order to evaluate intestinal BSH activity and its inhibition, we examined 
both the local ileal and systemic (blood) BA composition in the presence and absence of dietary BSH inhibitors. 
Both the ileal contents and blood samples were collected from each individual chicken (n = 10) at end point, day 
28, whether they were RS or NRS. Extracted samples were subjected to BA analysis following UPLC TMS based 
targeted analysis of 31 different BA moieties across the BA classes (Fig. 2a). For all samples, quality control spiking 
of each sample with internal standard deuterated cholic acid (D4 CA) prior to extraction allowed extraction effi-
ciency assessment and BA level normalization. D4 CA recoveries were in an acceptable range indicating efficient 
and accurate sample extraction for ileal samples (Fig. 2b).
Individual bile acid moieties were quantified against their corresponding standard curve, the data for each 
moiety is recorded along with any statistical significance relative to the control animals (Tables 2 and 3, respec-
tively). Interestingly, similar to rodents, control chicken ileal bile acid was dominated by tauro conjugated BA 
representing approximately 30% of total ileal BA while glyco conjugated BA was less well represented at just 0.3%. 
Figure 1. Body weight (BW) gain is influenced by BSH inhibitor treatment. Treatments were sub-divided 
according to responders (RS) and non-responders (NRS) and graphed relative to untreated control animals. 
BW gain is shown following treatment with (a) CAPE, (b) riboflavin and (c) carnosic acid via oral gavage for 21 
consecutive days. Corresponding values for actual weight gain are shown for (d) CAPE, (e) riboflavin and (f) 
carnosic acid. Data is represented as mean ± SD.
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Primary BA was 100 fold higher than glyco conjugated BA and secondary BA represented 0.1% of the total BAs 
featured. In collective comparisons with the control groups, BA moieties secondary BAs and glyco conjugated 
BAs appeared significantly reduced for all three BSH inhibitors treatments and for CAPE and riboflavin treated 
groups respectively. With RS and NRS stratification these effects were maintained. In addition, TLCA emerged as 
significantly reduced in RS animals with BSH inhibitor riboflavin.
Heatplots showed enrichment for secondary BA in the majority of control animals relative to BSH inhibitor 
treated animals (Figs. 3 and 4). Furthermore, BSH inhibitor activity enriched for conjugated BA (tauro and glyco) 
for the majority of treated animals. Further analysis indicated that while there was a trend towards higher levels 
of total BA on treated with either riboflavin or carnosic acid they did not reach significance (P > 0.05) relative 
to untreated animals (Fig. 3b). These trends were due to increased levels of tauro and glyco conjugated BAs 
(Fig. 3f,g), consistent with this, significantly lower levels of secondary BAs were detected for the BSH inhibitor 
treated groups (Fig. 3d). In addition, all of the BSH inhibitor treatment groups tended towards reduction for 
taurine relative to untreated control animals again suggesting that BSH inhibitors are active in vivo. Subsequently, 
individual secondary BAs were examined, to confirm that oral administration of each BSH inhibitor led to sig-
nificantly reduced levels of lithocholic acid (LCA) (P < 0.05; Fig. 4a). Riboflavin treatment showed the great-
est reduction in LCA (Fig. 4a) and it correlated with a trend towards higher levels of taurolithocholic acid 
(T-LCA) (Table 2). The level of muricholic acid in the intestine was significantly lowered by all of the treatments 
(Fig. 4c). Significantly lower levels of glycolithocholic acid, glycodeoxycholic acid, and glycoursodeoxycholic acid 
(Fig. 4b,d,f), all of which are conjugated secondary bile acids, were evident in the riboflavin treated group with 
similar trends evident where carnosic acid was applied. CAPE treatment alone, significantly reduced levels of 
glycochenodeoxycholic acid (Fig. 4e). Taken together these data support effective gastrointestinal BSH inhibition 
in treated animals leading to less microbial deconjugation and dehydroxylation to secondary BAs.
BSH inhibitor treatment altered circulating levels of bile acid. BAs actively transported into entero-
hepatic circulation are detectible in the blood. Table 4 summarizes the levels of different BA moieties detected in 
the plasma of untreated and BSH inhibitor treated animals. Only GHCA was significantly reduced in circulation 
by BSH inhibitors, whether each group was stratified as RS or not (Table 5). Plasma BAs varied among individual 
animals for all of the treatment groups (Fig. 5a). However, BA categories: total BAs, total conjugated BAs and their 
subdivided glyco and tauro conjugates, hydrophobic and hydrophilic BAs as well as secondary BAs showed no 
significant differences or even trends towards differences in their overall content (Fig. 5a–g). Individual BA moie-
ties were next examined (Fig. 6a) confirming that two bile acids LCA (Fig. 6b) and glyco hyocholic acid (G-HCA) 
(Fig. 6c) were significantly altered in response to CAPE and riboflavin BSH inhibitor. Riboflavin treatment ele-
vated LCA levels significantly (P = 0.0220) however trends towards increased LCA were evident for the remaining 
BSH inhibitors (Fig. 6b). No significant differences were evident for any other BA moieties in circulation.
Assessment of BA content as receptor agonists and antagonists. BA moieties can differentially 
alter gene expression through their interactions with bile acid receptors (BARS) including farnesoid X receptor 
(FXR), Takeda G protein couple receptor (TGR5), Vitamin D receptor (VDR) Pregnane X receptor (PXR) and 
Liver X receptor (LXR). The BA signatures generated could predict potential receptor interaction and signaling 
both locally in the ileum and in circulation to other tissues (Fig. 7). In the ileal, the combined levels of FXR 
antagonist (UDCA, TUDCA, GUDCA, T-MCA) was similar between the different groups. Interestingly, for all 
groups, the concentration FXR agonist (CA, CDCA, DCA, α-MCA and β- MCA) were within the same range but 
the level exceeded antagonist concentrations ca. 100 fold. In contrast, TGR5 agonists (LCA, DCA) were signifi-
cantly reduced for all BSH inhibitor treatments compared to control animals. The levels of BA moieties ligands 
for VDR (LCA, CDCA, DCA, CA), PXR (LCA, DCA, CA) and LXR (CA, LCA, DCA, CDCA, HDCA) remained 
unchanged (Fig. 7). BAs in circulation are relatively low compared to ileal BA levels (Fig. 7b), here no significant 
Figure 2. Assessment of Ileum bile acid extraction efficiency (a) Schematic of bile acid synthesis and 
subsequent microbial modifications from liver through the intestine indicating family and other classifications 
(b) Levels of internal standard deuterated cholic acid (D4 CA). Data is expressed as ng/mg of each sample and 
represented as mean ± SD.
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differences were detected between the treatment groups on the basis of NR or GPCR agonism. Taken together, 
this work indicates that signals that may be elicited at the level of the gut do not translate systemically.
BSH inhibitor treatment significantly altered host transcriptome profiles in the liver and the 
ileum. In order to assess gene transcription changes in the gut and in the liver one BSH inhibitor, carnosic 
acid (n = 4) was compared relative to untreated animals (n = 4), in order to assess gene transcription changes in 
the gut and in the liver by RNA-Seq. For BSH inhibitor treatment assessment they represented 1 RS and 3 NRS, 
based on body weight as described above. The high quality RNAs (reflected by RIN, Table S1) were extracted 
from tissue samples and applied for mRNA-Seq library construction and sequencing (Illumina Hi-Seq platform 
(150-cycle paired end). More than 685 million raw reads in pairs were obtained they ranged from 9.2 to 162.7 M 
raw reads per sample (Table S1). The mapping rate of RNA samples from liver samples and ileum samples ranged 
from 61.2% to 88.2%.
In response to carnosic acid, 607 DEGs (495 up-regulated and 112 down-regulated) were evident from 
liver tissue analysis while 215 DEGs (116 up-regulated and 99 down-regulated) were detected in the ileum. 
As expected, many DEGs are consistent with the reported function of carnosic acid, as an antioxidant and 
anti-inflammatory agent, partly demonstrating the success of RNA-Seq analysis. For example, of more than 600 
liver DEGs, approximately 80 DEGs were directly related to immunity and inflammatory response (data not 
Analyte (ng/mg) Control
Treatments
CAPE Riboflavin Carnosic acid
Taurine 31756.7 ± 21524.1 21578.8 ± 12308.8 17365.8 ± 8604.72 20219.9 ± 13145
1°
CA 18345.9 ± 13958 20972.6 ± 24376.8 20951.9 ± 21507 21497.1 ± 21009.5
CDCA 87807.5 ± 54654.3 71870.5 ± 73024.2 87413.3 ± 58895.8 81940.2 ± 87493
2° and 3°
DCA 93.62 ± 48.8161 110.46 ± 180.62 67.96 ± 45.2455 80.32 ± 69.0979
LCA 454.9 ± 139.222 203.43 ± 102.195 128.02 ± 22.5331 223.81 ± 146.359
UDCA 30 ± 13.9709 20.21 ± 10.4807 23.17 ± 11.3589 28.48 ± 21.5456
Free
DHCA 15.03 ± 11.0942 22.04 ± 11.1483 19.37 ± 10.5136 20.16 ± 12.134
HCA 128.7 ± 63.8126 207.72 ± 148.058 157.03 ± 120.701 284.59 ± 299.273
HDCA 110.73 ± 64.4569 81.24 ± 39.973 81.41 ± 49.4506 77.72 ± 45.1353
7-Keto LCA 792.32 ± 562.116 1208.6 ± 1017.19 928.98 ± 803.207 1724.7 ± 3102.9
MCA 31.04 ± 16.4731 14.65 ± 6.4469 10.53 ± 4.87751 15.76 ± 11.2074
Tauro-conjugated
TCA 176824 ± 141916 188001 ± 167087 337629 ± 307554 298425 ± 229751
THCA 909.59 ± 617.726 925.76 ± 635.741 1637.49 ± 1285.57 1833.4 ± 983.69
TCDCA 393422 ± 313666 261438 ± 230898 462709 ± 293324 420155 ± 229029
TUDCA 903.58 ± 569.553 628.88 ± 447.07 1343.18 ± 793.58 1028.05 ± 626.043
TDCA 231.21 ± 141.681 158.14 ± 105.343 301.33 ± 202.909 411.91 ± 454.826
THDCA 1306.84 ± 826.478 1340.12 ± 987.258 3307.76 ± 2348.69 1658.71 ± 886.923
TLCA 135.51 ± 59.7155 87.88 ± 70.023 215.82 ± 188.725 174.94 ± 129.549
Glyco-conjugated
GCA 885.3 ± 1054.44 586.53 ± 392.118 1652.2 ± 2115.93 1289.44 ± 1198.7
GHCA 61.18 ± 30.9591 47.97 ± 13.6454 41.31 ± 16.6029 48.24 ± 18.7021
GHDCA 127.72 ± 53.0436 88.46 ± 28.5804 73.82 ± 22.4606 92.14 ± 29.7437
GCDCA 572.46 ± 193.191 327.53 ± 169.58 691.44 ± 412.021 749.93 ± 759.147
GUDCA 125.04 ± 46.511 80.48 ± 40.9429 55.39 ± 10.6329 95.38 ± 36.2647
GDCA 125.59 ± 34.2556 78.98 ± 40.8439 46.24 ± 14.8928 89.35 ± 47.7493
GLCA 14.24 ± 7.45603 9.27 ± 4.95077 6.27 ± 4.07187 10.59 ± 8.0987
Muricholics
α-MCA 1250.77 ± 984.831 2035.6 ± 1539.72 1919.35 ± 1833.79 2408.9 ± 2679.91
β-MCA 1250.77 ± 984.831 2035.6 ± 1539.72 1919.35 ± 1833.79 2408.9 ± 2679.91
ω-MCA 233.53 ± 109.009 437.71 ± 320.029 631.33 ± 601.471 612.78 ± 684.997
α-TMCA 11587 ± 8181.47 10204.6 ± 6397.87 23976.8 ± 17716.8 17951 ± 10976.2
β-TMCA 11587 ± 8181.47 10204.6 ± 6397.87 23976.8 ± 17716.8 17951 ± 10976.2
ω-TMCA 11587 ± 8181.47 10204.6 ± 6397.87 23976.8 ± 17716.8 17951 ± 10976.2
Totals
Total BA 695718 ± 423098 559958 ± 423521 945071 ± 617788 851183 ± 508046
Total 1° BA 107827 ± 60839.3 95559 ± 96976.1 111107 ± 75539.5 106788 ± 109946
Total 2° BA 659.25 ± 184.045 395.13 ± 234.535 277.39 ± 107.463 381.85 ± 237.343
Total Free BA 108487 ± 60911.7 95954.1 ± 97140.1 111384 ± 75628.3 107170 ± 110110
Total Tauro BA 585320 ± 428580 462785 ± 368436 831120 ± 565041 741638 ± 442340
Total Glyco BA 1911.53 ± 1148 1219.22 ± 501.886 2566.67 ± 2482.77 2375.07 ± 1958.65
Table 2. Quantity of individual bile acids detected in ileal samples from chickens at end point (aged 28 days) 
treated or not with BSH inhibitors CAPE, riboflavin and carnosic acid. Data is shown as mean ± SD. All values 
are expressed in ng/mg.
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shown). A notable panel of DEGs involved in bile biosynthesis, lipid metabolism and relevant physiology were 
also observed. The representative DEGs in response to carnosic acid treatment are described in Table 6.
In addition to those involved genes in immune response (CD3E, OASL, BLB1), antioxidant and 
anti-inflammatory roles (glutamine synthetase, glutathione S-transferase), highly upregulated genes in liver were 
associated with BA metabolism (AKR1D1, PHGDH) and secondary metabolites biosynthesis (P450 CYP2C23a, 
CYP3A80, CYP4B7), lipid metabolism (APOD, LIPI), energy metabolism (AK1), glucose metabolism (PRKAG3), 
and insulin regulation (IGFBP5) (Table 6). Interestingly, the highest fold increases in liver gene transcription 
were detected for oligoadenylate synthetase (>10 fold). Oligoadenylate synthase (OAS) proteins sense exoge-
nous nucleic acid and initiate antiviral pathways and for major histocompatibility complex (>5 fold) initiating 
acquired immune system recognition. Growth factor binding protein (>3.8 fold increased) is a carrier of insulin–
like growth factor 1 (IGF-1); IGF-1 can exert positive or negative effects, depending on its levels and distribution 
All samples Responders
Statistical significance vs 
control
Statistical significance vs 
Control
Analyte 
(ng/mg) CAPE Riboflavin
Carnosic 
acid CAPE Riboflavin
Carnosic 
acid
Taurine ns ns ns ns ns ns
1°
CA ns ns ns ns ns ns
CDCA ns ns ns ↓ * ns ns
2° and 3°
DCA ns ns ns ↓$ ns ns
LCA ↓$ ↓$$$ ↓$ ↓ * ↓$ ns
UDCA ns ns ns ns ns ns
Free
DHCA ns Ns ns ns ns ns
HCA ns Ns ns ns ns ns
HDCA ns ns ns ns ns ns
7-Keto LCA ns ns ns ns ns ns
MCA ↓ * ↓$$ ↓* ↓ * ↓ * ns
Tauro-conjugated
TCA ns ns ns ns ns ns
THCA ns ns ns ns ns ns
TCDCA ns ns ns ns ns ns
TUDCA ns ns ns ns ns ns
TDCA ns ns ns ns ns ns
THDCA ns ns ns ns ns ns
TLCA ns ns ns ↓ * * ns ns
Glyco-conjugated
GCA ns ns ns ns ns ns
GHCA ns ns ns ns ns ns
GHDCA ns ↓$ ns ns ↓ * ns
GCDCA ↓** ns ns ns ns ns
GUDCA ↓* ↓$$ ns ns ↓ * ns
GDCA ↓* ↓$$$ ns ns ↓ * * ns
GLCA ns ↓$ ns ns ↓ * ns
Muricholics
α-MCA ns ns ns ns ns ns
β-MCA ns ns ns ns ns ns
ω-MCA ns ns ns ns ns ns
α-TMCA ns ns ns ns ns ns
β-TMCA ns ns ns ns ns ns
ω-TMCA ns ns ns ns ns ns
Totals
Total BA ns ns ns ns ns ns
Total 1° BA ns ns ns ↓ * ns ns
Total 2° BA ↓ * ↓$$ ↓* ↓ * ↓$ ns
Total Free 
BA ns ns ns ns ns ns
Total Tauro 
BA ns ns ns ns ns ns
Total Glyco 
BA ns ns ns ns ns ns
Table 3. Summary of statistical relevance for individual ileal bile acid levels from chickens at end point (aged 
28 days) treated or not with BSH inhibitors. All values are expressed in ng/mg. Statistical significance was 
calculated using Kruskal wallis: $p < 0.05; $$p < 0.01; $$$p < 0.001 followed by Mann Whitney t-Test (2-tailed): 
*p < 0.05; **p < 0.01; ***p < 0.001.
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to include apoptosis induction, or alteratively, cancerogenic cell proliferation. Negative DEGs in the liver include 
avium defensins 2, 6 and 1, their expression was reduced 83, 39 and 22 fold respectively. Furthermore, lysosomal 
innate immunity molecule cathelicidin was reduced 24 fold by carnosic acid treatment.
Ileal DEGs were not as profoundly altered when compared to those of the liver and changes were in the 
region of 4–5 fold were recorded. Here, upregulation of antioxidant and anti-inflammatory coding genes and 
transcription factors were evident, including oligoadenylate synthetase (5.5 fold) eomesodermin (3.1 fold) and 
glutathione S transferase (2.44 fold). Interestingly cell division checkpoint G0/G1 switch was up regulated (4.17 
fold). Regarding glucose metabolism, the fasting and energy reserve metabolism activator glucagon receptor was 
increased (2.8 fold).
Confirmation and validation of RNA-Seq analysis was performed by examining a number of DEGs associated 
with BA and lipid metabolism in the liver or ileum, by qRT-PCR analysis (Table 6). The qRT-PCR results are 
Figure 3. Assessment of the effects of BSH inhibitors on ileal bile acids classifications. (a) Heatplot showing 
relative representation of bile acids according to their classification/family for individual animals following 
respective treatments. Significantly altered (b–g) bile acid family representations. Coloured subjects represent 
responder (RS) animals with black subjects classified as non-responders (NRS).
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consistent with RNA-Seq analysis (Table 6), validating the expression of these genes and further demonstrating 
the integrity of RNA-Seq analysis.
GO enrichment analysis of differentially expressed genes. In order to compare functional enrichment 
between the carnosic acid and non-treated groups a total of 607 DEGs (495 up-regulated and 112 down-regulated) 
from liver samples and 215 DEGs (116 up-regulated and 99 down-regulated) from the ileum were subsequently 
applied for GO term enrichment analysis (Figs. 8 and 9). The majority of alterations were associated with meta-
bolic processes with 22.7% and 23.6% of up-regulated genes in liver and ileum, respectively and 14.6% and 15.8% 
down-regulated genes in liver and ileum, respectively. This was followed by cellular processes with 26.2% and 25.5% 
up-regulated genes in liver and ileum, respectively and 29.3% and 23.3% down-regulated genes in liver and ileum, 
respectively and then biological regulation with10.8% and 10.4% up-regulated genes in liver and ileum, respectively 
and 10.8% and 14.3% down-regulated genes in liver and ileum, respectively (Figs. 8 and 9).
Figure 4. Assessment of the effects of BSH inhibitors on ileal bile acid signatures. Only significantly altered 
BAs are show (a) lithocholic acid, (b) glycolithocholic acid, (c) muricholic acid, (d) glycodeoxycholic acid, (e) 
glycochenodeoxycholic acid and (f) glycoursodeoxycholic acid. Data is represented as mean ± SD. Colored 
subjects represent responder (RS) animals with black subjects classified as non-responders (NRS).
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Biochemical analyses of serum samples. The effects of all three BSH inhibitors relative to non treated 
controls were assessed for metabolic indicators including circulating lipid associated parameters (cholesterol, 
triglycerides, VLDL) and for glucose (Table 7). While BSH inhibitor treatment did not induce significant changes 
in the levels of circulating glucose (P = 0.08) glucose levels tended to be lower for all three BSH inhibitor treated 
groups. In contrast, total cholesterol levels appeared elevated in the treated groups (P = 0.33) a trend that was 
also consistent for VLDL (P = 0.18). Circulating triglyceride levels remained normal and equivalent among these 
different groups.
Discussion
The widespread use of AGPs are no longer encouraged through the food chain so that alternative approaches to 
mimic the effects of AGPs are being explored. AGP is correlated with reduced microbial population diversity 
and is therefore associated with the loss of microbial functionality to induce increased mass in animals for food 
supply. One such microbial function is BSH enzyme activity, a gateway activity for microbial conversion of BAs 
so that a palate of BAs are generated with different signaling abilities and lipid solubilization abilities. Increasing 
evidence implicates BSH activity in modulating host lipid metabolism and energy harvest in situ, we therefore 
speculated that BSH inhibitors could provide promising alternatives to AGPs in order to improve feed efficiency 
and body weight gain of animals as food.
Analyte (ng/
ml) Control
Treatments
CAPE Riboflavin Carnosic acid
Taurine 5158.07 ± 899.991 6119.81 ± 1686.87 5128.02 ± 1133.08 5486.31 ± 1619.6
1°
CA 48.9056 ± 39.2005 39.9222 ± 15.3336 136.97 ± 252.093 43.905 ± 30.3887
CDCA 317.872 ± 199.263 360.322 ± 296.289 505.175 ± 543.544 326.415 ± 276.1
2° and 3°
DCA 26.8833 ± 19.2574 24.5611 ± 9.93741 42.06 ± 71.8834 25.795 ± 14.5771
LCA 56.0667 ± 9.89854 72.6167 ± 15.1554 67.685 ± 8.9165 60.975 ± 10.3039
UDCA 5.25556 ± 5.5565 4.88889 ± 3.564 3.655 ± 1.58058 4.97 ± 3.98812
Free
DHCA 3.57778 ± 4.48993 2.55 ± 1.80509 1.48 ± 1.06775 3.28 ± 3.97355
HCA 7.82778 ± 6.25811 7.41111 ± 3.32138 7.135 ± 4.83591 6.9 ± 4.69628
HDCA 22.5333 ± 21.043 19.0778 ± 12.0967 16.285 ± 8.85362 22.505 ± 18.1956
7-Keto LCA 7.99444 ± 5.45601 8.65556 ± 2.31078 6.695 ± 2.01339 7.67 ± 4.621
MCA 5.84444 ± 3.79469 3.94444 ± 1.21528 6.25 ± 3.46143 6.19 ± 2.42
Tauro-conjugated
TCA 1801.21 ± 1397.4 1707.06 ± 582.066 2398.61 ± 1661.79 2185.07 ± 903.695
THCA 16.2111 ± 5.32326 16.3778 ± 2.41972 19.77 ± 17.0198 21.66 ± 8.78532
TCDCA 11004.2 ± 4887.34 9535.42 ± 3075.93 10664.2 ± 4217.4 11251 ± 5549.55
TUDCA 31.0833 ± 8.5127 32.6222 ± 9.67664 34.755 ± 11.8205 31.56 ± 19.5362
TDCA 13.7944 ± 4.11099 13.7 ± 1.29615 12.97 ± 3.29524 19.305 ± 14.531
THDCA 70.3333 ± 39.0954 70.9611 ± 31.3462 80.48 ± 34.1904 56.585 ± 27.8863
TLCA 15.25 ± 7.02416 19.0833 ± 4.97259 25.135 ± 17.9194 21.44 ± 8.82028
Glyco-conjugated
GCA 20.1278 ± 10.5564 17.7667 ± 3.73653 26.605 ± 28.3066 20.32 ± 5.24525
GHCA 16.1056 ± 4.36447 11.7444 ± 2.16826 9.655 ± 1.78556 15.045 ± 3.70732
GHDCA 22.1611 ± 6.134 21 ± 3.24953 18.64 ± 3.21044 21.91 ± 4.58633
GCDCA 50.1278 ± 14.0757 47.9389 ± 7.58708 51 ± 16.2255 52.435 ± 12.1855
GUDCA 24.5389 ± 8.98062 25.7167 ± 7.4087 24.935 ± 6.17823 24.79 ± 6.87193
GDCA 26.6111 ± 12.6429 31.7667 ± 2.62245 24.63 ± 3.26567 25.21 ± 5.55944
GLCA 3.78889 ± 3.28488 3.14444 ± 1.60476 2.9 ± 1.71625 3.205 ± 2.36859
Muricholics
α-MCA 19.4944 ± 14.6791 15.6889 ± 10.5338 38.98 ± 75.1296 18.03 ± 14.1154
β-MCA 5.83889 ± 6.58765 4.23333 ± 4.04523 5.36 ± 4.4882 6.23 ± 6.33862
ω-MCA 19.4944 ± 14.6791 15.6889 ± 10.5338 38.98 ± 75.1296 18.03 ± 14.1154
α-TMCA 299.844 ± 122.856 289.883 ± 103.64 439.265 ± 527.061 260.89 ± 98.2334
β-TMCA 299.844 ± 122.857 289.883 ± 103.65 439.265 ± 527.062 260.89 ± 98.2335
ω-TMCA 299.844 ± 122.858 289.883 ± 103.66 439.265 ± 527.063 260.89 ± 98.2336
Totals
Total BA 13931.9 ± 6497.58 12396.9 ± 3408.11 14663.1 ± 6641.96 14532.3 ± 6333.29
Total 1° BA 411.039 ± 241.842 436.411 ± 312.741 703.525 ± 873.1 412.64 ± 313.966
Total 2° BA 105.483 ± 48.5805 116.256 ± 24.3109 126.03 ± 78.1179 109.275 ± 35.4238
Total Free BA 516.522 ± 247.651 552.667 ± 313.649 829.555 ± 869.27 521.915 ± 316.28
Total Tauro BA 13251.9 ± 6283.48 11685.1 ± 3322.59 13675.2 ± 5964.74 13847.5 ± 6198.93
Total Glyco BA 163.461 ± 49.4592 159.078 ± 12.6049 158.365 ± 43.5747 162.915 ± 27.9597
Table 4. Quantity of individual circulating bile acids from chickens at end point (aged 28 days) treated or not 
with BSH inhibitors. Data is shown as mean ± SD. All values are expressed in ng/ml.
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To test this, in addition to in vitro identification of promising BSH inhibitors, examination of the in vivo 
efficacy of specific BSH inhibitor was performed with three novel and promising BSH inhibitors which we have 
identified and characterized namely riboflavin, CAPE, and carnosic acid10. Riboflavin is a vitamin participating 
in a range of redox reactions in the host12,13. It is applied as feed additive at low trace level in poultry feed (only 
2.5 ppm) to prevent and control the hypovitaminosis B2. However, long-term dietary supplementation of higher 
levels of riboflavin as BSH inhibitor for growth promotion in chicken and other food animals has never been 
explored. In fact, a previous study indicated that dietary supplementation of riboflavin increased feed efficiency 
and BW gain in pigs14, which may also be mediated through inhibition of intestinal BSH activity. Both CAPE 
and carnosic acid are emerging natural food additives that recently have attracted extensive attention for human 
and animal application. CAPE and carnosic acid have shown multiple bioactivities, such as anti-carcinogenic, 
anti-oxidation, and anti-inflammatory15–19. However, to date, little information exists concerning the effect of 
All animals Responders
Statistical significance vs 
Control
Statistical significance vs 
Control
Analyte 
(ng/ml) CAPE Riboflavin
Carnosic 
acid CAPE Riboflavin
Carnosic 
acid
Taurine ns ns ns ns ns ns
1°
CA ns ns ns ns ns ns
CDCA ns ns ns ns ns ns
2° and 3°
DCA ns ns ns ns ns ns
LCA ns ns ns ns ↑* ns
UDCA ns ns ns ns ns ns
Free
DHCA ns ns ns ns ns ns
HCA ns ns ns ns ns ns
HDCA ns ns ns ns ns ns
7-Keto LCA ns ns ns ns ns ns
MCA ns ns ns ns ns ns
Tauro-conjugated
TCA ns ns ns ns ns ns
THCA ns ns ns ns ns ns
TCDCA ns ns ns ns ns ns
TUDCA ns ns ns ns ns ns
TDCA ns ns ns ns ns ns
THDCA ns ns ns ns ns ns
TLCA ns ns ns ns ns ns
Glyco-conjugated
GCA ns ns ns ns ns ns
GHCA ↓* ↓$$ ns ns ↓$ ns
GHDCA ns ns ns ns ns ns
GCDCA ns ns ns ns ns ns
GUDCA ns ns ns ns ns ns
GDCA ns ns ns ns ns ns
GLCA ns ns ns ns ns ns
Muricholics
α-MCA ns ns ns ns ns ns
β-MCA ns ns ns ns ns ns
ω-MCA ns ns ns ns ns ns
α-TMCA ns ns ns ns ns ns
β-TMCA ns ns ns ns ns ns
ω-TMCA ns ns ns ns ns ns
Totals
Total BA ns ns ns ns ns ns
Total 1° BA ns ns ns ns ns ns
Total 2° BA ns ns ns ns ns ns
Total Free 
BA ns ns ns ns ns ns
Total Tauro 
BA ns ns ns ns ns ns
Total Glyco 
BA ns ns ns ns ns ns
Table 5. Summary of statistical relevance for individual circulating bile acid levels from chickens at end point 
(aged 28 days) treated or not with BSH inhibitors. All values are expressed in ng/ml. Statistical significance was 
calculated using Kruskal wallis: $p < 0.05; $$p < 0.01; $$$p < 0.001 followed by Mann Whitney t-Test (2-tailed): 
*p < 0.05; **p < 0.01; ***p < 0.001.
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CAPE and carnosic acid on host lipid metabolism and/or growth performance. One study reported that carnosic 
acid is involved in glucose and lipid metabolism20, which is likely partly dependent on the inhibitory effect of 
carnosic acid on BSH enzyme.
In this study, to better control BSH inhibitor dosage and delivery, we chose to perform cage trial and admin-
istered BSH inhibitor to each chick via oral gavage. Metabolomic analysis indicated that dietary supplementation 
of the BSH inhibitors did inhibit intestinal BSH activity and significantly changed BA profile, particularly in 
ileal towards higher levels of BA conjugates and lower levels of downstream secondary BAs. This effect can only 
be due to inhibition of deconjugation to provide BA precursors of secondary BAs6,7,21,22. Notably, secondary BA 
lithocholic acid (LCA), significantly decreased with all BSH inhibitor treatment. It is regarded as a cytotoxic com-
ponent in animal models, leading to reduced BW gain23–27 and it is implicated in colon carcinogenesis24. Indeed, 
addition of LCA to chicken feed increased animal plasma lipid levels, liver size but decreased liver fat deposition 
while inducing biliary hyperplasia in chicks26,27. More recently, LCA was also shown to impair nutrient uptake in 
Figure 5. Assessment of the effects of BSH inhibitors on circulating bile acid classifications: (a) Heatplot 
showing relative representation of bile acids according to their classification/family for individual animals 
following BSH inhibitor treatments. Significantly altered (b–g) bile acid family representations. Data is 
represented as mean ± SD. Coloured subjects represent responder (RS) animals with black subjects classified as 
non-responders (NRS).
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rat studies28. Importantly, LCA is a ligand for other lipid metabolism signaling factors including such as LXR29 
and PXR30. Its cognate tauro conjugate is decreased in these BSH inhibitor treated groups, which serves as an 
activator of inflammatory dampening through Takeda Receptor (TGR5) present in a range of tissues includ-
ing macrophage31. TGR5 can also influence host energetics through thyroid hormone activation and increased 
energy expenditure, browning of white adipose tissue and through FGF21 activation and by stimulating secretion 
of incretin glucagon-like peptide (GLP)-1, to release insulin to alter blood glucose levels, gastrointestinal motility 
and satiety. Finally, some BSH inhibitor-mediated BA changes may further enhance host energy harvest, βMCA 
and TCA, (both FXR activators) were elevated in BSH treatment groups they may alter BA, lipid and glucose 
metabolism32,33.
Despite the evidence to support effective BSH inhibitor treatment in this cage trial, it is not surprising that 
the differences in BW gain and feed efficiency were not always statistically significant at the different time points 
examined. BW gain and feed efficiency assessment for broiler chicken are usually large (n = 10 bird per pen with 
10 pens per treatment)11. BW gain and feed efficiency in this cage trial were lower than those observed in tradi-
tional pen trial, since cage design (away from ground with hanging feeder) may have caused loss of feed, reduced 
accessibility of small chicks to feeder and water, lowered the density of young chicks (3–4 per cage). Consequently, 
low feed efficiency was observed across all groups. Despite these limitations, this cage trial indicates that all three 
BSH inhibitors enhanced BW gain and feed efficiency, and also significantly changed the bile acid profile due to 
inhibition of BSH activity, providing a strong rationale for us to perform large scale pen trials in the future.
Figure 6. Assessment of the effects of BSH inhibitors on circulating bile acid signatures (a) heatplot showing 
relative representation of individual bile acid moieties for individual animals following their respective 
treatments. (b) lithocholic acid and (c) glycohyocholic acid levels are significantly altered in plasma samples 
following either CAPE or riboflavin treatments, similar trends are evident with carnosic acid. Data is 
represented as mean ± SD. Coloured subjects represent responder (RS) animals with black subjects classified as 
non-responders (NRS).
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In addition to analysis of BA alterations we performed RNA-Seq analysis to evaluate the local and systemic 
impacts of the BSH inhibitor carnosic acid. The findings from RNA-Seq analysis in this study not only supported 
in vivo inhibition of intestinal BSH by carnosic acid but also showed the influence of this BSH inhibitor upon 
local (gut) and systemic (liver) regulators of lipid metabolism. In the liver AKR1D1 was induced by carnosic acid, 
Tand it functions in BA synthesis to transform 7-α-hydroxycholesterol to primary bile acids (cholic acid and 
chenodeoxycholic acid)34. Notably, expression of a panel of host Cytochrome P450 enzymes, such as CYP2C23a, 
CYP3A80, CYP4B7, are also significantly induced upon carnosic acid treatment (Table 4). P450 enzymes are 
active determining the fate of cholesterol to either hormones or BAs35. To date, the functions of the P450 enzymes 
are still largely unknown in chicken. Due to the high similarity between chicken CYP3A80 and human CYP3A4 
(59% sequence identity), CYP3A80 may catalyze the 6-hydroxylation of LCA as observed for CYP3A436,37.
Of the DEGs identified in ileum tissue samples, the upregulated G0S2 and the downregulated ACER2 are of 
particular interest. The G0S2 gene is highly conserved in vertebrates and is a master regulator of tissue-specific 
balance of triglyceride storage and mobilization, partitioning of metabolic fuels between the adipose tissue, the 
liver and the whole body adaptive energy response38. G0S2 is a lipolysis inhibitor by inhibiting adipose triglyc-
eride lipase which is responsible for catalyzing the first step of three stepwise reactions that define lipolysis38,39. 
In addition, G0S2 is also a target gene for peroxisome proliferator activated receptor (PPARα), a transcription 
factor participating in lipid metabolism and adipogenesis40. ACER2 is critical in metabolism of bioactive lipid 
sphingolipids41–43, downregulation of ACER2 upon carnosic acid may lead to changes in serum LDL, HDL and 
cholesterol level44.
Clearly, all the three selected BSH inhibitors are predicted to display off target effects and our RNA-Seq anal-
ysis supports this notion. Carnosic acid is a known anti-oxidant with anti-inflammatory and anti-carcinogenic 
properties17,45,46, and it enhanced a range of immune and inflammation responses in both liver and ileum tis-
sues. Carnosic acid can exert its anti-oxidant effects by the activation of the PI3K/Akt/Nrf2 signaling pathway17 
to induce the Nrf2-targeted gene GSTA347,48, which is also upregulated in ileum in this study. Carnosic acid 
treatment resulted in liver downregulated endogenous host defense peptide (HDP), including AvBD1, AvBD2, 
AvBD6, Cathelicidin-1, and Cathelicidin-2, important first line of defense against microbial infections49–51 
Therefore, further examination of the influence of carnosic acid on susceptibility to microbial infection is highly 
Figure 7. Prediction of (a) Ileal and (b) circulating bile acid receptor activation post BSH inhibitor treatment 
relative to non treated animals. Agonists (+) and antagonists (−) for FXR; agonists for TGR5, VDR and PXR 
are represented. Data is represented as mean ± SD.
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Genea Description of gene product
Fold 
change by 
RNA-Seq
Fold 
change by 
qRT-PCRb
Liver
Upregulated
  00000007416 (CD3E) CD3e molecule 1.78 ND
  00000013723 (OASL) Oligoadenylate synthetase-like 10.39 ND
  00000000141 (BLB1) Major histocompatibility complex 5.33 ND
  00000012834 (AKR1D1) Aldo-keto reductase 2.70 3.02
  00000002988 (PHGDH) Phosphoglycerate dehydrogenase 2.13 ND
  00000006995 (APOD) Apolipoprotein D 4.40 ND
  00000015662 (LIPI) Lipase 2.03 ND
  00000029150 (AK1) Adenylate kinase 2.74 ND
  00000011360 (PRKAG3) Protein kinase 3.89 ND
  00000005795 (CYP2C23a) Cytochrome P450 family 4.72 ND
  00000004436 (CYP3A80) Cytochrome P450 family 1.76 1.66
  00000010469 (CYP4B7) Cytochrome P450 family 2.13 ND
  00000008518 (LOC417253) Glutamine synthetase-like 2.02 ND
  00000016325 (GSTA3) Glutathione S-transferase 3.85 2.19
  00000008409 (GSTO1) Glutathione S-transferase 1.79 ND
  00000028551 (LOC100859645) Glutathione S-transferase-like 2.34 ND
  00000011468 (IGFBP5) Growth factor binding protein 3.88 ND
Downregulated
00000024272 (S100A9) Calcium binding protein −4.02 −3.98
00000003876 (TIMD4) T-cell immunoglobulin and mucin −1.76 ND
00000022815 (AvBD1) Avian beta-defensin 1 −22.37 ND
00000016669 (AvBD2) Avian beta-defensin 2 −83.19 ND
00000016668 (AvBD6) Avian beta-defensin 6 −39.80 −15.50
00000027973 (CATH1) Cathelicidin-1 −24.74 ND
00000019696 (CATH2) Cathelicidin-2 −11.43 ND
00000016710 (CYP39A1) Cytochrome P450 family −1.63 ND
00000016426 (MAP3K15) Mitogen-activated protein kinase −2.86 ND
00000021039 (HKDC1) Hexokinase −2.87 ND
00000005845 (SLC7A5) Solute carrier family −1.99 ND
Ileum
Upregulated
  00000013723 (OASL) 2′-5′-oligoadenylate synthetase-like 3.35 ND
  00000027247 (EOMES) Eomesodermin 3.18 ND
  00000016400 (RSAD2) Radical S-adenosyl methionine domain 2.81 ND
  00000007395 (ABCC2) ATP-binding cassette 2.18 ND
  00000013969 (ALDH8A1) Aldehyde dehydrogenase family 1.7 ND
  00000016325 (GSTA3) Glutathione S-transferase 2.44 2.22
  00000015702 (PTGR1) Prostaglandin reductase 2.45 ND
  00000023933 (G0S2) G0/G1 switch 4.17 3.10
  00000008845 (HAO1) Hydroxyacid oxidase 2.35 ND
  00000002466 (SLC2A5) Solute carrier family 1.92 ND
  00000013969 (ALDH8A1) Aldehyde dehydrogenase 1.70 ND
  00000005795 (CYP2C23a) Cytochrome P450 family 2.31 ND
  00000011219 (GCGR) Glucagon receptor 2.85 ND
Downregulated
00000016164 (ABCG1) ATP-binding cassette −3.71 −2.60
00000015081 (ACER2) Alkaline ceramidase −3.20 −1.35
00000028519 (CCR10) C-C motif chemokine receptor −3.61 −2.33
00000015441 (CD247) CD247 molecule −1.77 ND
00000006480 (TCF7) Ttranscription factor −2.92 ND
00000006707 (NOX1) NADPH oxidase −2.60 ND
00000005572 (NOXO1) NADPH oxidase organizer −3.32 ND
00000001857 (FAM132A) Family with sequence similarity 132 member −2.35 ND
Continued
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Genea Description of gene product
Fold 
change by 
RNA-Seq
Fold 
change by 
qRT-PCRb
00000014766 (HAO2) Hydroxyacid oxidase −3.78 ND
00000026817 (LOC771638) Hydrogenase/reductase −2.89 ND
Table 6. Differentially expressed genes (DEGs) in response to carnosic acid treatment in liver and ileum 
tissues. Results were determined based on DAVID bioinformatics resources (https://david.ncifcrf.gov/). The 
genes denoted as Upregulated are those having significantly higher expression level in carnosic acid treatment 
group than those in the control group; genes denoted as Downregulated are those having significantly lower 
expression in carnosic acid treatment group than those in the control group. aGene is expressed as ENSGALG 
gene ID number followed by corresponding gene name in parentheses. bMeans of four individual tissue samples 
with triplicate measurement for each sample. ND, not determined.
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activity (GO:0016247)
signal transducer
activity (GO:0004871)
structural molecule
activity (GO:0005198)
receptor activity
(GO:0004872)
binding
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Ileum
Ileum
Figure 8. Functional enrichment of Gene Ontology or up-regulated transcripts detected from chicken liver 
and ileum in response to carnosic acid treatment. Functional enrichment of differentially abundant genes 
was analyzed by Gene Ontology Consortium with GO Enrichment Analysis tool (http://www.geneontology.
org/page/go-enrichment-analysis). The set of differentially abundant genes was functionally annotated with 
DAVID bioinformatics resources (https://david.ncifcrf.gov/). (a) Up-regulated genes classified with the specific 
biological process terms, (b) Up-regulated genes classified with the specific molecular function terms, (c) Up-
regulated genes classified with the specific cellular component terms.
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Figure 9. Functional enrichment of GO terms of down-regulated transcripts in chicken liver and ileum in 
response to carnosic acid treatment. Functional enrichment of differentially abundant genes was analyzed 
by Gene Ontology Consortium with GO Enrichment Analysis tool (http://www.geneontology.org/page/
go-enrichment-analysis). The set of differentially abundant genes was functionally annotated with DAVID 
bioinformatics resources (https://david.ncifcrf.gov/). (a) Down-regulated genes classified with the specific 
biological process terms, (b) Down-regulated genes classified with the specific molecular function terms, (c) 
Down-regulated genes classified with the specific cellular component terms.
Biochemical 
Parameters Control CAPE Riboflavin Carnosic Acid P value
Glucose (mg/dL) 224.49 ± 12.78 189.96 ± 7.98 186.32 ± 6.81 186.58 ± 7.45 0.08
Total Cholesterol (mg/
dL) 96.94 ± 6.98 91.84 ± 6.61 105.26 ± 7.57 110.61 ± 7.96 0.33
Triglycerides (mg/dL) 42.69 ± 3.58 40.20 ± 3.35 39.35 ± 3.28 41.86 ± 3.47 0.85
VLDL (mmol/L) 11.53 ± 0.67 14.35 ± 1.49 16.43 ± 2.55 14.38 ± 1.95 0.18
Table 7. Biochemical analyses of chicken serum following BSH inhibitor treatment. The concentrations of 
serum glucose, triglycerides, total cholesterol and very low density lipoprotein (VLDL) were expressed as 
mean ± standard error. Statistical significant level of difference is defined by P < 0.05.
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warranted. Nevertheless, the implications from this and other animal work is that these BSH inhibiting com-
pounds may induce healthy weight gain rather than simply fat mass, therefore the use of these inhibitors could be 
highly desirable as an alternative to AGPs.
The majority of our knowledge base for food, microbes and BA metabolism comes from rodents and their 
translation to humans, there are considerable knowledge gaps in animal husbandry52,53. There are many inci-
dences where this work does not translate, due simply to copy number classes of enzymes, fundamental meta-
bolic differences and to signaling. The extent to which chicken systems are characterized in terms of metabolism, 
microbiota, receptor signaling and the host microbe dialogue is an emergent area for discovery particularly in 
addressing AGP alternatives. Further comprehensive nutritional, physiological, microbiome, genomics and 
metabolomics measurements associated with BSH inhibitor use are warranted to accurately determine their 
mode of action, degree of penetrance and indeed whether any growth promotion in animal husbandry can be 
achieved through healthy means.
Materials and methods
Chicken management, experimental design and sample collection. All of the methods described 
below were performed in accordance with the relevant guidelines and regulations. Chicken experiment was 
reviewed and approved by the University of Tennessee Institutional Animal Care and Use Committee (IACUC 
No. 2187). Forty newly hatched male broilers from Hubbard LLC (Pikeville, TN, USA) were raised in the Joseph 
E. Johnson Animal Research and Teaching Unit (JARTU, Knoxville, TN, USA). 7 days old chicks were randomly 
allocated into four groups (n = 10/group). They received one of caffeic acid phenethylester (Wuhan Yuancheng 
Gongchuang Tech, Wuhan, Hubei, China), riboflavin (Bulk Supplements, Henderson, NV, USA), carnosic acid 
(Purify, Chengdu, Sichuan, China) at 25 mg/kg, or simply control solution (50% propylene glycol), via oral gavage 
once a day for 21 consecutive days. The dosage was adjusted accordingly based on average chicken BW deter-
mined on Day 7, 10, 14, 17, 21, and 24. Water and feed were available ad libitum during the project. On Day 7, 
10, 14, 17, 21, 24, and 28, BW and feed consumption were recorded. On Day 28, blood samples were collected 
from the brachial vein of each bird. Following blood sampling, all birds were euthanized by CO2 asphyxiation 
and dissected for sampling. The ileal contents were collected from all birds, transferred to sterile cryogenic vials, 
immediately frozen on dry ice and stored at −80°C prior to shipment for metabolomic analysis. Approximately 
5 cm of ileum from each chicken was collected and rinsed with saline (0.9% sodium chloride, w/v); the cleaned 
ileum and a sample of liver tissue from each bird were immediately frozen in liquid nitrogen and stored in cry-
ogenic vials at −80°C prior to extraction for RNA-Seq analysis. The blood samples were centrifuged at 4,000 g 
for 15 min; subsequently, the supernatant (serum) was aliquoted in sterile cryogenic vials and stored in −80 °C 
freezer prior to further analysis.
Serum biomarker analyses. The concentrations of glucose, triglycerides, total cholesterol, and very 
low-density lipoprotein (VLDL) in each serum sample were determined by using following commercial kits: 
Glucose Colorimetric Assay Kit and Triglyceride Colorimetric Assay Kit (Cayman Chemical, Ann Arbor, MI, 
USA; for glucose and triglyceride), EnzyChrom Cholesterol Assay Kit (Bioassay System, Hayward, CA, USA; for 
total cholesterol), Chicken very low density lipoprotein, VLDL ELISA kit (Novatein Biosciences, Woburn, MA, 
USA; for VLDL).
Bile acid profile analyses. Serum and ileal contents samples from individual chickens were packaged 
on dry ice and shipped for ‘blinded’ metabolomics measurements and statistical analysis. The extracted BAs 
from each sample were analyzed by Ultra Performance Liquid Chromatography-Tandem Mass Spectrometry 
(UPLC-TMS). The procedures for BA extraction, characterization and quantification were detailed in a previous 
publication8.
RNA extraction and RNA-Sequencing. For each liver or ileum tissue sample (n = 4 for control and for 
treated groups for each tissue type) total RNA was extracted using Qiagen RNeasy mini kit (Qiagen Inc., Valencia, 
CA, USA) following the manufacturer’s instructions. The RNA integrity number (RIN), concentration and the 
28 S/18 S ratio of RNA were then evaluated using Agilent RNA 600 Nano kit with Agilent 2100 Bioanalyzer 
(genomics Hub, University of Tennessee Institute of Agriculture, USA). The total RNA samples were stored at 
−80 °C prior to analysis. Extracted RNA was packaged on dry ice and shipped to the DNA Facility at Iowa 
State University (Ames, IA, USA) for mRNA-Seq library construction and RNA-Seq. Overall, sixteen sequencing 
libraries were constructed from RNA samples and subjected to sequencing using Illumina HiSeq 3000 system 
(150-cycle paired-end high-output sequencing).
RNA-Seq differential gene expression analysis. The RNA-Seq differential gene expression analysis 
was performed in the Office of Advanced Research Computing (Rutgers University, NJ, USA). The raw reads were 
quality trimmed using Trimmomatic-0.33 with leading and trailing Q score 25, minimum length 25 bp, and min-
imum length 50 bp. The cleaned reads were mapped to Gallus_gallus genome - 5.0 version, using Tophat v.2.0.13. 
The reference genome sequence and annotation files were downloaded from ENSEMBLE, release.87 (Gallus_gal-
lus.Gallus_gallus-5.0.dna.toplevel.fa and Gallus_gallus.Gallus_gallus-5.0.87.gtf). The aligned read counts were 
obtained using htseq-count as part of the package HTSeq-0.6.1.The Bioconductor package edgeR_3.1.2 with 
limma_3.22.7 was used to perform the differential gene expression analysis in R Studio v 1.0.143. The differen-
tially expressed genes (DEGs) between the control group and carnosic acid group were identified at combined 
cut-offs with p value <0.05 and fold change>1.5. The DEGs were uploaded to DAVID Bioinformatics Resources 
(https://david.ncifcrf.gov/) online bioinformatics analysis system for functional annotation and canonical path-
way analyses.
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GO enrichment analysis of differentially expressed genes. After gene annotation with DAVID-BR, 
Gene Ontology (GO) analysis (http://www.geneontology.org/page/go-enrichment-analysis) was applied to inves-
tigate the underlying functions (i.e., biological process, molecular function and cellular component). The P value 
denoted the significant of the GO term enrichment among differentially expressed genes (Adj P-value < 0.05).
Real-time quantitative reverse transcription-PCR (qRT-PCR). Key PCR primers applied to this study 
are listed in Table 8. Extracted RNA (200 ng) was used for cDNA synthesis using Thermo Scientific RevertAid 
First Strand cDNA synthesis kit (Cat#: K1621) according to the manufacturer instructions. The qPCR assays 
were performed using iTaq universal SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA, USA). Briefly, 
cDNA was diluted 10-fold, and 1 μL of each diluted sample was added to a 10-μL reaction mix containing 50 ng of 
forward and reverse primers of specific target gene. The β-actin house-keeping gene was used as an internal refer-
ence to normalize target gene transcript levels54. Reactions were conducted in triplicate. The threshold cycle (CT) 
values for genes of interest were normalized to an average CT value of the house-keeping genes and the relative 
expression of replicate was calculated by applying the 2-ΔΔCt method55.
Statistical analysis. Chicken BW, BW gain, FCR, the levels of serum biomarkers (glucose, total choles-
terol, triglycerides, VLDL) were compared among treatments using mixed model analysis of variance procedure. 
Analyses were conducted with SAS v9.4 (SAS Institute, Cary, NC, USA) and least squares means were compared 
at the significance level of P less than 0.05. BA analysis was performed using Waters MassLynx Software V4.2 
SCN943 (Waters Corporation, USA). Prism 7.0 (GraphPad Software Inc., La Jolla, CA) was applied for graphic 
construction. For heatplot generation data was plotted using RStudio software version 1.1.453. Statistical signifi-
cance for BA samples was calculated using using Kruskal wallis: $P < 0.05; $$P < 0.01; $$$P < 0.001 followed by 
Mann Whitney t-Test (2-tailed): *P < 0.05; **P < 0.01; ***P < 0.001.
Data availability
RNA-Seq data generated for this study have been deposited in the National Center for Biotechnology and 
Information (NCBI) Sequence Read Archive (SRA) with accession number SRP149780.
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